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ABSTRACT
Allosteric mechanisms are widely used in nature
to control the rates of enzymatic reactions, but little
is known about RNA catalysts controlled by these
principles. The only natural allosteric ribozyme
reported to date catalyzes an RNA cleavage reac-
tion, and so do almost all artificial systems. RNA
has, however, been shown to accelerate a much
wider range of chemical reactions. Here we report
that RNA catalysts for organic reactions can be put
under the stringent control of effector molecules
by straight-forward rational design. This approach
uses known RNA sequences with catalytic and
ligand-binding properties, and exploits weakly con-
served sequence elements and available structural
information to induce the formation of alternative,
catalytically inactive structures. The potential and
general applicability is demonstrated by the design
of three different systems in which the rate of a
catalytic carbon–carbon bond forming reaction is
positively regulated up to 2100-fold by theophylline,
tobramycin and a specific mRNA sequence, respec-
tively. Although smaller in size than a tRNA, all three
ribozymes show typical features of allosteric meta-
bolic enzymes, namely high rate acceleration and
tight allosteric regulation. Not only do these find-
ings demonstrate RNA’s power as a catalyst, but
also highlight on RNA’s capabilities as signaling
components in regulatory networks.
INTRODUCTION
The reversible control of chemical reaction rates by external
trigger signals is of great interest from both a fundamental
and an application perspective. Catalytic reactions are par-
ticularly attractive and nature has evolved elaborate mecha-
nisms of allostery to control enzymatic reaction rates by
the concentration of effector molecules. These mechanisms
are the basis of feedback inhibition in biochemistry and con-
stitute a central principle of biological regulation (1–3).
Allosteric chemical systems, however, are scarce and limited
to a few carefully designed supramolecular and organometal-
lic systems (4–6), mainly owing to our poor understanding of
the structural preconditions for switching between catalyti-
cally active and inactive conformations of small molecules.
Ribozymes have been converted successfully into allosteric
systems by either combinatorial selection or rational design,
and both simple oligonucleotides and a variety of other
molecules (from metal ions and small organic molecules to
peptides and large proteins) were used as effectors (7–11).
These catalysts are RNA enzymes whose activity is modu-
lated by effector binding to a domain located apart from
the active site (12–15). Although most natural ribozymes cat-
alyze RNA-modifying (i.e. RNA-cleaving or ligating) reac-
tions, ribozymes identiﬁed by combinatorial chemistry were
found to accelerate a much wider spectrum of chemical reac-
tions, including C-C, C-N, C-O and C-S bond formation
or cleavage, and even redox chemistry [for current reviews
see (16,17)].
Ligand-induced conformational changes in RNA mole-
cules were discovered recently as an important regulatory
principle in gene expression. Riboswitches are metabolite-
sensing RNAs typically located in the non-coding portions
of messenger RNAs where they control the synthesis of
metabolite-related proteins in many species (18,19). More
than 2% of the genes in some bacterial species are regulated
by riboswitches, and to date, riboswitches have been identi-
ﬁed that respond to 10 fundamental metabolites. Typically,
a conformational switch in the sensing domain upon ligand
binding alters the base-pairing arrangements in the adjoining
expression platform, thus modulating transcription, transla-
tion or RNA processing events. Recently, a class of catalytic
riboswitches was discovered that induce a self-cleavage (i.e.
an RNA-catalyzed RNA cleavage) reaction on binding a
sugar phosphate metabolite (20).
Phosphodiester chemistry constitutes only for a very small
fraction of all biochemically relevant reactions, and the excel-
lent predictability of catalyst–substrate interactions in RNA-
catalyzed RNA cleavage reactions clearly sets these systems
apart from typical protein enzymes. This latter feature not
only allows the rational design of sequence-speciﬁc nucleases
by the non-specialist, it also facilitates the incorporation of
regulatory modules into the same molecule; both extremely
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Therefore, allosterically controlled ribozymes that catalyze
reactions involving small-molecule substrates would arguably
more closely resemble nature’s allosteric enzymes and would
allow a direct comparison of the regulatory strategies and
the underlying structural principles. From an application per-
spective, such catalysts would offer opportunities to control
the rates of chemical reactions for which neither natural
enzymes nor synthetic catalysts exist.
Our lab has discovered previously a ribozyme that cat-
alyzes the formation of C–C bonds by Diels-Alder reaction,
a reaction type of fundamental importance in organic
chemistry. We have accumulated extensive knowledge on
the structure and reaction mechanism of this ribozyme, and
very recently the 3D structure was solved by X-ray crystal-
lography (21–26). This high amount of structural information
renders the Diels-Alderase attractive for the development of
allosteric systems. Although we reported recently the ﬁrst
isolation of an allosterically controlled non-phosphodiester
ribozyme by combinatorial selection (27), we now investigate
different strategies for rational construction of Diels-Alderase
ribozymes that are positively regulated (i.e. switched on) by
external effector molecules.
Although one cannot convert an inactive RNA sequence
into a catalyst by design, it is quite easy to manipulate a cat-
alytically active sequence to fold into an inactive conforma-
tion (7,28,29). For allosteric regulation, active and inactive
conformation should be at equilibrium, which is shifted
by ligand binding. Using the Diels-Alderase ribozyme as
the catalytic platform, we directly attach three structurally
different ligand-binding modules without intervening spacer
sequences. Weakly conserved sequence elements in both
domains are used to create alternative structures and to
optimize and ﬁne-tune the relative stabilities of the compet-
ing active and inactive structures. The key to allostericity
lies in this delicate balance, and the three examples provided
below illustrate different ways to modulate the rate of
catalytic cycloaddition reactions.
MATERIALS AND METHODS
General
Theophylline, tobramycin and biotin maleimide were purch-
ased from Sigma. Anthracene-deca (ethylene glycol) guano-
sine monophosphate was provided by Dr R. Fiammengo (30).
DNA transcription templates and short RNA oligonucleotides
(Bcr/Abl and Abl/Abl) were purchased from IBA Go ¨ttingen,
Germany. RNA–tether–anthracene conjugates were prepared
by enzymatic synthesis (T7-RNA polymerase; Stratagene or
MBI Fermentas) in the presence of optimized concentrations
of anthracene-deca (ethylene glycol)-guanosine monophos-
phate as transcription initiator, which allowed the preparation
of ribozymes with covalently tethered anthracene (30). Tran-
scription products were puriﬁed by PAGE. For radioactive
labeling of oligonucleotides, [a-
32P]CTP and [g-
32P]ATP
(Amersham) were used.
Ribozyme activity assays
Decay kinetics of the ﬂuorescence of covalently tethered
anthracene were monitored by spectroﬂuorimetry (JASCO).
Exitation, 365 nm (slit width 1 nm); emission, 419 nm
(slit width 10 nm). The change in ﬂuorescence (dNFS/dt)
translates linearly into change in substrate concentration
(d[Antracene]/dt). Reactions were carried out in reaction buf-
fer (ﬁnal concentrations 30 mM Tris–HCl, pH 7.4, 5 mM
MgCl2 and 300 mM NaCl) at 25 C. The concentration of
ribozyme was varied between 1 and 4 mM. All components
were mixed, allowed to incubate for 15 min and the start ﬂuo-
rescence value (100%) was recorded. The reaction was
started by the addition of biotin maleimide (ﬁnal concentra-
tion: 25 mM, from a 1 M stock solution in dimethyl sulfox-
ide). Effector concentrations were 100 mM for theophylline
and 10 mM for tobramycin. For the Bcr/Abl system, the
stoichiometry of the three components (left fragment:right
fragment:mRNA) was 1:1:2. Kinetic ﬂuorescence–time
curves of all catalytically active constructs are provided as
online Supplementary Data.
RESULTS
Design principles and structural analysis of the systems
The operating principle of the allosteric systems described
here is the stabilization of catalytically inactive conforma-
tions by direct interference of sequence elements of both
domains. On binding the effector, this stabilizing interference
is overcome and the RNA refolds into a catalytically active
conformation (Figure 1). This approach uses complementary
stretches of nucleotides that are either already present in the
Figure 1. Rational design of allosteric ribozymes operating by direct
inactivating interference. An aptamer and a ribozyme are fused, and different
interactions are either identified (red) or designed (green, purple) that cause
folding into a stable alternative structure. Effector binding induces refolding.
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tors, red) or can be incorporated at weakly conserved posi-
tions by mutation (artiﬁcial inactivators, green and purple).
In addition to the formation of alternative secondary struc-
tures, the approach may also involve the disruption of critical
tertiary contacts. Thus, the ﬁrst step in the development of
such systems is the careful analysis of the parental sequences
for original inactivators and weakly conserved positions,
leading to an initial design. In subsequent steps, the system
is gradually modiﬁed and optimized.
The reaction catalyzed by the Diels-Alderase ribozyme is
shown in Figure 2a, together with the simpliﬁed secondary
structure. Although this ribozyme is capable of multiple-
turnover catalysis, a single-turnover in cis reaction format
(with the anthracene diene covalently tethered to the RNA)
is used throughout this study. The blue and green helices
were found to be variable in both size and sequence, while
for the yellow helix a length of 4 bp is conserved. The
50-G1-G2-A3-G4 segment plays a critical role in shaping
both the RNA scaffold and the catalytic pocket. All four resi-
dues align through Watson–Crick base pairing with residues
on both sides of the asymmetric bubble segment (dotted black
lines in Figure 2a), thereby generating a complex nested
pseudoknot topology and leading to a lambda-shaped overall
structure. In Figure 2a, the bases of the 50-GGAG end and
of the asymmetric internal bubble are color-coded according
to their conservation level (for details see caption). Figure 2b
shows the tertiary structure of the ribozyme with Diels-Alder
reaction product (cyan) bound inside the preformed catalytic
pocket as observed in the crystal structure (21,24). Figure 2c
and d shows the theophylline (31,32) and tobramycin (33,34)
aptamer secondary structures (with the conserved positions
in red), their effectors and their 3D structures with the
bound effectors shown (in cyan). The various non-conserved
or weakly conserved nucleotides found provide ample oppor-
tunities for molecular design.
Design of theophylline-responsive Diels-Alderase
ribozymes
The sequences of the Diels-Alderase ribozyme and the theo-
phylline aptamer (31) contain a complementary 5 nt stretch
(yellow box, Figure 3) that represents the starting point for
the design. Ribozyme and aptamer were fused directly by
deleting the ribozyme’s upper stem–loop and the aptamer’s
lower stem (Figure 3a). Two artiﬁcial inactivators were intro-
duced by mutation, one leading to an alternative aptamer
structure (red box) and the other causing the ribozyme’s
50 end hybridizing to its 30 end (gray box). According to
this initial design, three different double-strand interactions
(shown as red, yellow and gray boxes) would stabilize the
inactive structure, while four stems (indicated by blue, pur-
ple, green and red letters) would stabilize the active form.
The activity of all constructs in the absence or presence of
theophylline was determined by monitoring the decrease of
the anthracene ﬂuorescence at 419 nm as the result of the
Diels-Alder reaction (22,27) (Figure 3c). The construct repre-
senting the initial design, Theo 1, showed greatly reduced
activity, compared to the non-regulated Diels-Alderase
ribozyme, but exhibited an 9-fold activation by theophylline
(for kinetic curves see Supplementary Figure S1). To improve
allostericity we next systematically varied the strength of the
Figure 2. RNA molecules utilized in the design of allosteric ribozymes. (a) Secondary structure of the Diels-Alderase ribozyme and catalyzed reaction. Green
and blue stem–loop structures are completely variable in size and sequence, while the yellow helix is variable in sequence, but conserved in size. Nucleotides in
red are invariant; orange, highly conserved (over 90% activity reduction on mutation); purple, pair-wise complementary substitutions allowed; gray, strong
preference for 2 nt; black, variable (<50% activity reduction on mutation); black dotted lines, Watson–Crick pseudoknot base pairs. (b) Tertiary structure of
the Diels-Alderase ribozyme with the reaction product (cyan) bound inside the catalytic pocket. (c) Theophylline aptamer secondary structure (conserved
residues in red, variable in black), effector formula and 3D structure with the theophylline in cyan. (d) Tobramycin aptamer secondary structure, effector formula
and 3D structure with bound tobramycin (cyan).
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by lengthening the red box (black arrows in Figure 3a and b)
lead to totally inactive construct Theo 2, which could not be
reactivated by shortening the gray box (gray arrows, Theo 3).
Starting over with Theo 1, we attempted to destabilize the
inactive structure by shortening the red box from three to
two base pairs (red arrow, Theo 4), which had only marginal
effect on the rates. In construct Theo 5, the active structure
was additionally stabilized by lengthening the green stem
(green arrows), i.e. the direct interface between ribozyme
and aptamer domain. This signiﬁcantly increased the reaction
rate in the presence of theophylline and lead to an activation
factor of  50 (Figure 3b and c). Further destabilization of the
inactive structure (shortening of the yellow box from 5 to
3 bp, blue arrow) created a constitutively active ribozyme
Theo 6 that did not respond to theophylline anymore. On
the other hand, a slight destabilization of the active form
(by replacing one G–C base pair by A–U starting from
Theo 3, pink arrows) gave completely inactive construct
Theo 7.
Apparently, Theo 5 provides the optimal balance of stabili-
ties of the active and inactive conformations to allow effector
binding to shift the equilibrium towards the catalytically
active conformation. The original inactivator (yellow box)
is necessary for the proper balance between active and inac-
tive conformation, and mutations that disrupt this element
abolish allostericity. The optimal length for the intra-aptamer
inactivator (red box) is 2 bp, and stronger inactivators tended
to eliminate ribozyme activity. For the stabilization of the
active structure, the interface region was found to be particu-
larly important (green letters).
Tobramycin-responsive Diels-Alderase ribozymes
In contrast to the previous system, no suitable complementary
stretches exist in the tobramycin aptamer (34), and we have to
design a system based solely on artiﬁcial inactivators. The
main design principle is alternative pairing of the nucleotides
forming the two helices above and below the catalytic pocket
of the Diels-Alderase ribozyme, which are partially variable
(see above, Figure 2a). Thus, in the initial design, Tob 1,
the upper stem–loop of the Diels-Alderase was cut off and
replaced by the published tobramycin aptamer sequence
(Figure 4a). The sequence of the interconnecting stem was
designed so that slippage could create an inactive structure
with a 5 bp stem (yellow box), involving the CCA of the
left side of the catalytic pocket and the terminal U of
the right half. The active structure, on the other hand,
would be stabilized by two 4 bp helices (blue and red letters).
Tob 1 showed some allostericity; the activation factor was
about 4.
To increase the stabilities of both the inactive and active
structures, one A–U base pair in each structure was replaced
by G–C (Tob 2), requiring a total of three point mutations
(black arrows in Figure 4a and b), thereby increasing the
allostericity to about 9. For both Tob 1 and Tob 2, we next
attempted to selectively increase the stability of the inactive
structure by increasing the length of the yellow box. The
attempt to use 4 (rather than 3) nt of the left side of the
catalytic pocket was unsuccessful and lead to completely
inactive constructs Tob 3 and Tob 4 (blue arrows). The use
of 3 (instead of 1) nt of the right side (red arrows), however,
requiring the substitution of C19 by G, and (owing to a
known tertiary interaction, Figure 2a and b) a compensatory
Figure 3. Design of theophylline-dependent Diels-Alderase ribozymes. (a) The Diels-Alderase ribozyme (left) and the theophylline aptamer (right) are fused
after removing the upper and lower helix, respectively, leading to the starting design Theo 1. Colored boxes indicate interactions that stabilize the inactive
structure. Colored letters show interactions that stabilize the active structure. Colored arrows indicate positions of mutations leading to molecules Theo 2 to Theo
7. (b) Systematic investigation of interactions that stabilize or destabilize the active (left, colored letters) or inactive (right, colored boxes) structures. The colored
arrows indicate the positions of mutations and correspond to (a). Black circle, inactive molecule; green circle, constitutively active molecules; red circle,
allosteric molecule; two red circles, good allostericity. Numbers indicate the allosteric switching factor, defined as the initial rate in the presence of effector
divided by the initial rate in the absence of effector. (c) Fluorescence–time curve for Theo 5 in the presence (red) and absence (green) of theophylline. NFS (%) is
normalized fluorescence signal.
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showed excellent allostericity with activation factors of
35 and 52, respectively. This result demonstrates that knowl-
edge about the 3D structure is helpful, and in some cases may
be required to reach the allosteric design goal.
A Diels-Alderase ribozyme under the control of
a Bcr/Abl messenger RNA sequence
In this third example, a three-component allosteric system is
created that can be switched on by a fragment of malignant
Bcr/Abl mRNA, a chimeric transcription product involved
in a genetic disorder causing chronic myeloid leukemia. As
an additional requirement, the system should not only be
inactive in the absence of the Bcr/Abl mRNA fragment, but
also in the presence of an oligonucleotide corresponding to
the non-malignant Abl/Abl mRNA. Therefore, a short stretch
of nucleotide sequence around the junction of the two exons
should be speciﬁcally recognized (Figure 5).
A tetranucleotide AAUA occurs both in the Bcr RNA close
to the junction point and in the catalytic core of the Diels-
Alderase where it is important for the formation of the ter-
tiary structure (yellow box). This feature was used as starting
point. A bipartite Diels-Alderase was designed by replacing
the major part of the upper Diels-Alderase stem–loop struc-
ture by binding arms complementary to the Bcr2/Abl2 frag-
ment around the junction point. As the sequence of this
upper stem is variable, we extended the AAUA fragment
of the catalytic pocket to CAAUA. Thus, the 30-GUUAU-50
fragment of the left binding arm has two potential binding
partners; one in the Bcr/Abl mRNA (if present) and one
inside the ribozyme’s catalytic center.
This design shows excellent allostericity (Figure 5). Only
in the presence of the Bcr2/Abl2 RNA effector oligo-
nucleotide, a signiﬁcant catalytic activity can be measured
(red curve). In the absence of effector RNA, the reaction
rate is indistinguishable from the uncatalyzed background
reaction (black curve). Allosteric activation is at 2100-fold.
The Abl1/Abl2 RNA lacking the competing pentanucleotide
fragment failed to activate the Diels-Alderase (blue curve).
A mutant ribozyme in which the yellow box of the left bind-
ing arm was replaced by a non-complementary sequence
showed signiﬁcant residual activity in the absence of effector
RNA, highlighting the importance of the stable inactivating
interaction (green curve).
DISCUSSION
In this study, we report the ﬁrst examples of allosteric RNAs
that catalyze reactions different from phosphodiester chem-
istry constructed by a straight-forward rational approach
(12). The three examples start from different structural situa-
tions and use chemically very different effectors; from a
small purine alkaloid bound mainly by stacking (32) to an
aminoglycoside antibiotic that is recognized by hydrogen
bonds from RNA bases and sugars to the target (33), to a
large RNA sequence recognized purely by canonic base pair-
ing. In all three cases, good to excellent allostericity with
switching factors of 50–2100 could be achieved. It is note-
worthy that in each case, even the initial design displayed
signiﬁcant allostericity (9-, 4- and 2100-fold, respectively).
Although higher allosteric activation factors have been
reported for some RNA-cleaving ribozymes (9,10), the values
Figure 4. Design of tobramycin-dependent Diels-Alderase ribozymes. (a) The Diels-Alderase ribozyme (left) and the tobramycin aptamer (right) are fused after
removing the ribozyme’s upper helix, leading to the starting design Tob 1. The yellow box indicates interactions that stabilize the inactive structure. Colored
letters (red and blue) show interactions that stabilize the active structure. Colored arrows indicate positions of mutations leading to molecules Tob 2 to Tob 6.
(b) Systematic investigation of interactions that stabilize or destabilize the active (left, colored letters) or inactive (right, colored boxes) structures. The colored
arrows indicate the positions of mutations and correspond to (a). Black circle, inactive molecule; red circle, allosteric molecule; two red circles, good
allostericity. Numbers indicate the allosteric switching factor, defined as the initial rate in the presence of effector divided by the initial rate in the absence of
effector. (c) Fluorescence–time curve for Tob 6 in the presence (red) and absence (green) of tobramycin. NFS (%) is normalized fluorescence signal.
5036 Nucleic Acids Research, 2006, Vol. 34, No. 18achieved here are in the range of most allosteric protein
enzymes in nature (12), and sufﬁcient for the development
of sensors and assays (11,35–37). The rationally designed
theophylline-dependent ribozyme compares favorably with
the one isolated in our lab by in vitro selection from a
combinatorial library (27).
Rationally designed inactivating interactions have been
applied previously to RNA-cleaving ribozymes (most of
them under the control of oligonucleotide effectors)
(7,28,29,38,39). All these systems capitalize on the pre-
dictable nature of canonic base pairing for catalyst–substrate
and/or catalyst–effector interaction (13). Here we show that
even in cases where Watson–Crick base pairing governs nei-
ther of these interactions, it can be used to switch the
ribozymes into inactive conformations. Switching efﬁciency
depends on the relative stabilities of the active and inactive
conformations, and the delicacy of these equilibria is high-
lighted by the ﬁnding that only in one case (Bcr/Abl) the
ribozyme is completely inactive in the absence of effector.
In the other two systems, the rate in the absence of effector
is still one to two orders of magnitude above the uncatalyzed
background reaction (22). Furthermore, several of the kinetic
curves show reproducible irregularities and multiphasic
behavior, suggesting the involvement of multiple conforma-
tions or subpopulations (e.g. Tob 2; Supplementary Data).
The three analytes chosen for this study are all of practical
medicinal relevance: theophylline as a brochodilator in
asthma therapy, tobramycin as an antibiotic and the chimeric
Bcr/Abl transcription product as an important tumor marker.
For all three, there is a need for sensitive and robust analytics.
The Diels-Alderase generates a directly measurable ﬂuores-
cence signal and the allosteric constructs allow detecting
and determining these analytes (27). The (unregulated)
Diels-Alderase was shown previously to act with fast multi-
ple turnovers (up to 7 min
 1) on free anthracene substrates,
which are very sensitive ﬂuorophores (23). The rational
design approach outlined here may therefore allow the
development of sensitive ribozyme-based assays for a variety
of analytes without the need for dye-labeled RNA substrate
molecules. As the Diels-Alderase was shown to be cata-
lytically active when immobilized (40), surface- and chip-
based assays developed for other allosteric ribozymes might
work, too (36,41).
The two aptamers and the one mRNA sequence used in this
study were selected solely on the basis of published sequence
data without prior experiments, indicating that this approach
is general with respect to the ligand-binding RNA. It uses
general design principles and is probably not restricted to
Diels-Alderase ribozymes. We predict that most of the
known ‘artiﬁcial’ ribozymes can be rationally put under the
control of effectors following these lines, thereby allowing
control of the rate of various organic reactions by effector
molecules. The only strict requirement is knowledge about
sequences and conservation levels for both domains, and
additional structural information helps to integrate tertiary
interactions into the design.
With sizes under 70 nt, the three ribozymes are even smal-
ler than a tRNA, yet catalyze a demanding organic reaction
and they are tightly controlled by their effectors. Not only
does this demonstrate the power of RNA as a biocatalyst,
but also raises the question whether similar roles are played
by RNA in biology. Regulation and signaling are considered
to be major biological functions of RNA, and both the
currently known riboswitches (18–20) and the recently dis-
covered microRNA based signaling mechanisms appear to
be only the tip of an iceberg (42,43). Although these latter
mechanisms process information by speciﬁc recognition of
RNA sequences and subsequent recruitment of proteins, in
the systems developed here a small-molecule input signal
(the concentration and the chemical identity of theophylline
and tobramycin, respectively) or a sequence input signal
(in the Bcr/Abl system) is catalytically converted into
small-molecule output signal (identity and concentration of
Diels-Alder product). We propose that (yet undiscovered)
Figure 5. Design of mRNA-responsive Diels-Alderase ribozymes. (a) The upper stem–loop structure of the Diels-Alderase ribozyme was replaced by binding
arms that specifically recognize the Bcr2/Abl2 mRNA. The yellow box indicates interactions that stabilize the inactive structure. Colored letters (blue, red, green)
show interactions that stabilize the active structure. (b) Fluorescence–time curves for the different combinations that are shown in (a). The experiment leading to
the green curve (control) is identical to that corresponding to the black curve (no mRNA), except that it uses a ribozyme in which the yellow GUUAU box in the
binding arm was replaced by CAAUA. NFS (%) is normalized fluorescence signal.
Nucleic Acids Research, 2006, Vol. 34, No. 18 5037RNA catalysts for small-molecule chemistry may be involved
in biological signaling to integrate RNA and conventional
small-molecule signaling.
SUPPLEMENTARY DATA
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